ClinicalTrials.Veeva

Menu

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

Weill Cornell Medicine (WCM) logo

Weill Cornell Medicine (WCM)

Status and phase

Completed
Phase 2

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia

Treatments

Drug: Cytarabine
Drug: Mylotarg

Study type

Interventional

Funder types

Other

Identifiers

NCT00195000
0403-762

Details and patient eligibility

About

The purpose of this study is to find out how safe and effective the combination of Mylotarg in combination with cytarabine is in treating patients with Acute Myeloid Leukemia and advanced Myelodysplastic Syndrome over the age of 60 years.

Full description

To evaluate the safety and efficacy of gemtuzumab ozogamicin in combination with cytarabine in inducing complete remission in patients with AML and advanced MDS over the age of 60 years.

Patients eligible for treatment will receive the following:

Mylotarg at 6 mg/m2 on day 1 as a 2 hour intravenous infusion

Cytarabine at 100 mg/m2/day as a continuous intravenous infusion daily for 7 days

Enrollment

43 patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologic diagnosis of AML or advanced MDS
  • No prior cytotoxic treatment for AML. (patients may have been treated with prior biologic therapy) Patients with MDS or AML that has evolved from MDS, could have received prior low-dose cytotoxic therapy (i.e. azacytidine or low-dose ara-C).

Exclusion criteria

  • Uncontrolled or severe cardiovascular disease or pulmonary disease

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems